Physician profile
Samir Rahbe
NPI 1073665642
$2,902.21
in general payments reported to CMS, 2019-2025
34 companies · $607 in 2025
The $607 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $594 · 2021: $361 · 2022: $303 · 2023: $222 · 2024: $526 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $359.56 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $339.02 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $314.44 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $218.91 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
| Janssen Pharmaceuticals, INC | $207.99 | 2019-2022 | |
| Lilly USA, LLC | $125.57 | 2020-2024 | Mounjaro, Jardiance |
| Lundbeck LLC | $119.34 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $98.26 | 2019-2021 | |
| Amarin Pharma, INC. | $97.22 | 2019-2021 | |
| Amgen INC. | $84.15 | 2023-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $83.14 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $81.87 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $79.05 | 2023-2025 | Gvoke Hypopen |
| Intra-Sana Laboratories | $78.99 | 2024-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Akcea Therapeutics, INC. | $65.85 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $58.12 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.57 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $46.10 | 2024-2025 | |
| Abbvie INC. | $44.99 | 2021-2022 | |
| Eisai INC. | $44.32 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $36.02 | 2024 | Fanapt |
| Sumitomo Pharma America, INC. | $32.83 | 2024-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.11 | 2020-2024 | |
| Inspire Medical Systems, INC. | $29.02 | 2024 | Inspire |
| Glaxosmithkline, LLC. | $26.64 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $21.50 | 2022 | |
| Novo Nordisk INC | $19.94 | 2022 | |
| Scpharmaceuticals INC. | $19.94 | 2024 | |
| Medtronic, INC. | $17.71 | 2025 | Kyphon Express II Kyphopak Tray |
| Acadia Pharmaceuticals INC | $16.16 | 2022 | |
| Mylan Specialty L.P. | $14.62 | 2019 | |
| Amicus Therapeutics, INC. | $14.61 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.84 | 2023 | Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Rahbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.